PDGFRA mutation

•KIT/PDGFRA mutations in metastatic, imatinib-resistant #GIST •Prior Tx selects for resistant A-loop mutations •ctDNA resistance mutations prognosticate efficacy of 3rd/4th-line TKI @Annals_Oncology @DrCeSarcoma @SteveBialickDO @seppobauer S. George https://t.co/Mgzutsu317 (@JTrentMDPhD)

📰in Annals of Oncology, investigators studied the landscape of KIT & PDGFRA mutations in metastatic, imatinib-resistant GIST using ctDNA sequencing 🩸🧪🧬 on pre and post-treatment plasma samples in the VOYAGER clinical trial https://t.co/6y16OZsbyt @JTrentMDPhD @DrCeSarcoma (@Annals_Oncology)

KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial https://t.co/3dxDyIp0ei (@PestanaRC)

Probably this is transformed AML from Eosinophilia. Just need to check if the NGS shows PDGFRA D842V mutation. If this mutation present , then it won’t respond to imatinib. Avapritinib is drug of choice. We had similar patient whom we transplanted in CR1. Relapsed with EM disez. (@SujayRainchwar)

37/F, De Novo AML with FIP1L1-PDGFRa mutation, post 7+3 in CR. Should we continue low dose Imatinib maintenance with FIP1L1-PDGFRa PCR monitoring or go for upfront alloSCT? (10/10 MUD available.) Need your expertise @nihardesai7 @AaronGoodman33 @SujayRainchwar @NutanJoshi27 (@DigambarPanchal)

Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor #GIST harboring heterogenous KIT/PDGFRA mutations ⁦@seppobauer⁩ ⁦@schoffski⁩ ⁦@jeanyvesblay⁩ ⁦@GinaDAmatoMD1⁩ ⁦@SylvesterCancer⁩ https://t.co/rwLy6Gh01X (@JTrentMDPhD)

Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations. @schoffski @KU_Leuven @ctosociety #CTOS2020 #scmsm https://t.co/rSSRzRCj66 (@OncLive)

Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST @schoffski @KU_Leuven #scmsm https://t.co/VfRXsIyFEk (@OncLive)

Next week, I’ll evaluate a patient with metastatic GIST and PDGFRA D842V mutation. Avapritinib and ripretinib are not approved in Brazil. Is there a way for compassionate access to these drugs outside the USA? @JTrentMDPhD @DrCeSarcoma @Deciphera @BlueprintMeds @VivekSubbiah (@PestanaRC)

Hay varios tipos de cáncer de estómago. Este fármaco sólo vale si son tumores del estoma gastrointestinal (GIST) con la mutación en PDGFRA D842V, que es un tipo de tumor bastante raro (@DrCeSarcoma)

Avapritinib in advanced PDGFRA D842V-mutant #GIST ⁦@sciencedirect⁩ ⁦@TheLancetOncol⁩ ⁦@schoffski⁩ ⁦@RobinL_Jones⁩ ⁦@rutkowskip1972⁩ ⁦@WTapMD⁩ ⁦@DrCeSarcoma⁩ https://t.co/ZLS73J5rsX (@JTrentMDPhD)

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial - ScienceDirect https://t.co/IqLLZXsm1l (@VivekSubbiah)

According to a press release from Blueprint Med. the 476 patient Phase 3 VOYAGER trial of avapritinib vs. regorafenib in GIST did not meet the progression-free survival endpoint; the company is discontinuing development of avapritinib in GIST beyond PDGFRA exon 18 mutant GIST (@schoffski)